News – Page 982 – Endpoints News

CheckMate-451: Bristol-Myers’ Opdivo — plus Yervoy — fails PhIII combo lung cancer study, the latest in a ...

7 years ago

Vivek Ramaswamy ramps up biotech startup #14 — this time working on a gene therapy for sickle cell disease and ...

7 years ago

GW Pharma shares surge on positive PhIII followup; Illumina leads $18M round for Stilla's DNA tech

7 years ago

After falling off a cliff, Edge Therapeutics provides cancer-focused PDS Biotech a reverse merger onto Nasdaq

7 years ago

Rolling up its sleeves, Axovant scoops up five gene therapy vets to propel new pipeline

7 years ago

Déjà vu for Zafgen: Still fretting about lingering cardio concerns, FDA clamps a hold on lead obesity drug -- ...

7 years ago

In a landmark first, Chinese scientist claims birth of genetically modified babies — and all hell breaks loose

7 years ago

Vectura sinks after PhIII asthma trial ends in failure, marking another setback

7 years ago

Playing a hot hand in cancer R&D, Pfizer scores its 4th drug approval in just 2 months

7 years ago

Roivant joins forces with Korea's iNtRON Bio to fight superbugs; Evotec inks deal to leverage AI to develop drugs

7 years ago

Pfizer wants to reel back contributions to Hyde-Smith after her remarks about ‘public hanging’ spark controversy

7 years ago

Roche ties up again with Ascletis — this time on a commercial partnership for hep B drug

7 years ago

Gurnet Point-backed Auregen taps Amgen vet to lead; Ex-Roche RNA chief takes CEO post at Genevant

7 years ago

Jury finds former Aveo CFO David Johnston liable for scheme to mislead investors

7 years ago

Novartis banks on the promise of digital therapeutics in the management of chronic disorders

7 years ago

Clozel hands over a rival to PTC’s controversial steroid deflazacort — now in a pivotal study for Duchenne MD

7 years ago

Sobi’s $50M bet on a rare disease drug pays off with a quick FDA nod

7 years ago

Eli Lilly vet takes helm at Brickell Biotech; Stemline's Elzonris secures speedy EU review

7 years ago

FDA opts to nail down REMS plan for Sage's landmark postpartum depression drug, delays final decision

7 years ago

Who are the best — and worst — among the major pharmas at developing drugs for the poor?

7 years ago

Takeda clears final regulatory hurdle to completing its $62B Shire deal. Now only one obstacle remains

7 years ago

Stallergenes Greer's dust mite allergy drug clears pivotal study, edges closer to approval

7 years ago

As power shifts hands in Washington, a top analyst predicts an unavoidable war over rising drug prices

7 years ago

Germany's Merck forges JV with Thiel's Palantir to harness data to attack cancer

7 years ago

First page Previous page 979 980 981982983 984 985 Next page Last page